Long noncoding RNAs as biotargets in cisplatin-based drug resistance

Future Oncol. 2018 Dec;14(29):3085-3095. doi: 10.2217/fon-2018-0303. Epub 2018 Nov 23.

Abstract

Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.

Keywords: biomarker; cisplatin; lncRNA; noncoding RNA; platinum.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cisplatin / pharmacology*
  • Cisplatin / therapeutic use
  • Down-Regulation
  • Drug Resistance, Neoplasm / genetics*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / metabolism*
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • RNA, Long Noncoding
  • Cisplatin